Compare
Dianthus Therapeutics, Inc. vs Lipocine Inc. vs Bio Essence Corp vs GeoVax Labs, Inc.
| Latest fiscal year | Dianthus Therapeutics, Inc. DNTH | Lipocine Inc. LPCN | Bio Essence Corp BIOE | GeoVax Labs, Inc. GOVX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $2.04M | $1.98M | $1.90M | $2.49M |
| Revenue growth (YoY) | -67.3% | -82.3% | +485.8% | -37.1% |
| Gross margin | n/a | n/a | 75.3% | n/a |
| Operating margin | n/m | -524.7% | 47.4% | -869.3% |
| Net margin | n/m | -487.1% | 47.2% | -862.3% |
| Net income | -$162.34M | -$9.63M | $896.2K | -$21.46M |
| EPS (Diluted) | -$4.20 | -$1.69 | n/a | n/a |
| Operating cash flow | -$129.06M | -$9.76M | $1.57M | -$21.47M |
| Free cash flow | n/a | n/a | n/a | -$21.50M |
| Cash & equivalents | $51.09M | $5.21M | n/a | $3.09M |
| Total assets | $530.92M | $17.01M | $422.5K | $6.34M |
| Total liabilities | $37.52M | $2.53M | $2.50M | $2.52M |
| Shareholders' equity | $493.40M | $14.48M | -$2.07M | $3.83M |
| Return on year-end equity | -32.9% | -66.5% | n/a | -561.2% |
| Shares outstanding | 43.22M | 6.16M | 38.01M | 1.73M |
Revenue, most recent five fiscal years
| Fiscal year | Dianthus Therapeutics, Inc. | Lipocine Inc. | Bio Essence Corp | GeoVax Labs, Inc. |
|---|---|---|---|---|
| Latest | $2.04M Ended 2025-12-31 | $1.98M Ended 2025-12-31 | $1.90M Ended 2025-12-31 | $2.49M Ended 2025-12-31 |
| 1 year earlier | $6.24M Ended 2024-12-31 | $11.20M Ended 2024-12-31 | $323.9K Ended 2024-12-31 | $3.95M Ended 2024-12-31 |
| 2 years earlier | $2.83M Ended 2023-12-31 | -$2.85M Ended 2023-12-31 | $551.5K Ended 2023-12-31 | $0 Ended 2023-12-31 |
| 3 years earlier | n/a | $500.0K Ended 2022-12-31 | $621.6K Ended 2022-12-31 | $81.5K Ended 2022-12-31 |
| 4 years earlier | n/a | $16.14M Ended 2021-12-31 | $888.0K Ended 2021-12-31 | $385.5K Ended 2021-12-31 |